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ABSTRACT Despite success in viral inhibition and CD4 T cell recovery by highly ac-
tive antiretroviral treatment (HAART), HIV-1 is still not curable due to the persistence
of the HIV-1 reservoir during treatment. One patient with acute myeloid leukemia
who received allogeneic hematopoietic stem cell transplantation from a homozy-
gous CCR5 Δ32 donor has had no detectable viremia for 9 years after HAART cessa-
tion. This case has inspired a field of HIV-1 cure research focusing on engineering
HIV-1 resistance in permissive cells. Here, we employed a glycosylphosphatidylinositol
(GPI)-scFv X5 approach to confer resistance of human primary CD4 T cells to HIV-1. We
showed that primary CD4 T cells expressing GPI-scFv X5 were resistant to CCR5 (R5)-,
CXCR4 (X4)-, and dual-tropic HIV-1 and had a survival advantage compared to control
cells ex vivo. In a hu-PBL mouse study, GPI-scFv X5-transduced CD4 T cells were selected
in peripheral blood and lymphoid tissues upon HIV-1 infection. Finally, GPI-scFv X5-
transduced CD4 T cells, after being cotransfused with HIV-infected cells, showed signifi-
cantly reduced viral loads and viral RNA copy numbers relative to CD4 cells in hu-PBL
mice compared to mice with GPI-scFv AB65-transduced CD4 T cells. We conclude that
GPI-scFv X5-modified CD4 T cells could potentially be used as a genetic intervention
against both R5- and X4-tropic HIV-1 infections.
IMPORTANCE Blocking of HIV-1 entry is one of most promising approaches for ther-
apy. Genetic disruption of the HIV-1 coreceptor CCR5 by nucleases in T cells is under
2 clinical trials and leads to reduced viremia in patients. However, the emergence of
viruses using the CXCR4 coreceptor is a concern for therapies applying single-
coreceptor disruption. Here, we report that HIV-1-permissive CD4 T cells engineered
with GPI-scFv X5 are resistant to R5-, X4-, or dual-tropic virus infection ex vivo. In a pre-
clinical study using hu-PBL mice, we show that CD4 T cells were protected and that GPI-
scFv X5-transduced cells were selected in HIV-1-infected animals. Moreover, we show
that GPI-scFv X5-transduced CD4 T cells exerted a negative effect on virus replication in
vivo. We conclude that GPI-scFv X5-modified CD4 T cells could potentially be used as a
genetic intervention against both R5- and X4-tropic HIV-1 infections.
KEYWORDS CD4 protection, GPI-anchored scFv, HIV-1, gene therapy, humanized
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Although new infections by human immunodeficiency virus type 1 (HIV-1) havedecreased 35% since 2000, as of 2014, there are still approximately 36.9 million
people living with HIV-1 (59). The implementation of highly active antiretroviral treat-
ment (HAART) has dramatically reduced morbidity and mortality associated with AIDS
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and prolonged the life expectancy of individuals infected with HIV-1 (1). Nonetheless,
the cessation of HAART results in a rapid rebound of viral replication and ensuing CD4
depletion due to the persistence of HIV-1-infected reservoir cells. As a result, patients
need lifelong adherence to antiretroviral drugs to control HIV-1 infection (2). The
appearance of drug resistance (3, 4) as well as severe adverse side effects (5) led the
scientific community to explore curative approaches that control viral replication in the
absence of HAART and restore immune function. Cure of HIV-1 infection remains the
major challenge to global public health.
The only “functional cure” case so far is known as the “Berlin patient,” who received
transplantation of hematopoietic stem cells from a CCR5 Δ32 homozygous donor prior
to interruption of antiretroviral therapy. After HAART interruption, HIV-1 in lymphoid
tissues of this patient has remained undetectable for 9 years, giving rise to the hope for
a cure of HIV-1 infection (6). CCR5 (R5) is the major coreceptor required for HIV-1 entry
(7). Individuals with a naturally occurring homozygous mutant CCR5 gene (CCR5 Δ32)
express truncated dysfunctional CCR5, resulting in resistance to HIV-1 infection without
adverse health effects (8, 9). One of the underlying benefits of CCR5 disruption in the
Berlin patient is the inhibition of new infection by R5-tropic HIV-1 strains. This case
indicates that enabling HIV-1 target cells to resist virus entry can prevent viral infection
and restore functional immune cells or even the immune system.
To date, many approaches have been tested to modify autologous HIV-1-susceptible
cells to prevent virus entry. As a choice of top priority, profound efforts have been made
to knock down or knock out CCR5 expression, including the use of intrabodies (10), RNA
interference (RNAi) (11–13), transcription activator-like nucleases (TALENs) (14, 15), zinc
finger nucleases (ZFNs) (16–21), and clustered regularly interspaced short palindromic
repeat (CRISPR)-CAS9 nucleases (22, 23). Preclinical evaluation of CCR5 disruption by
ZFNs has been tested in a humanized mouse model. Mice engrafted with gene-
modified cells displayed reduced viremia, selection of CCR5-disrupted cells, and pro-
tection of CD4 T cells in peripheral blood and lymphoid organs when challenged with
R5-tropic virus (16, 19). A more recent clinical trial using CCR5-disrupted autologous
CD4 T cell transplantation showed a relative survival advantage during treatment
interruption and improved trafficking to rectal mucosa of modified cells (24), suggest-
ing the safety, persistence, and resistance to infection of gene-modified CD4 T cells in
infected patients. However, at a late stage of infection in patients, viruses using the
other coreceptor, CXCR4 (X4), emerge, which is correlated with rapid disease progres-
sion (25, 26). The shift of HIV-1 tropism to CXCR4 was also reported for humanized mice
transplanted with CCR5-disrupted hematopoietic stem cells as well as one patient who
received an adoptive transfer of stem cells with the CCR5 Δ32 mutation (27). Ap-
proaches to block CXCR4 expression were also developed (21, 28–30), but CXCR4
disruption alone exhibited only partial protection upon X4-tropic virus infection (28).
However, simultaneous editing of CCR5 and CXCR4 conferred robust protection against
CD4 loss in humanized mice infected with R5- and X4-tropic viruses (31).
An alternative approach to protect HIV target cells from both R5- and X4-tropic
HIV-1 strains utilizes a membrane-bound C-peptide entry inhibitor (maC46), which is
derived from the C-terminal heptad repeat 2 (HR2) region of HIV-1 Env gp41 (32, 33).
Cells expressing mC46 alone (32) or mC46 combined with other antivirus factors (34,
35) were resistant to both R5-tropic and X4-tropic virus infections in humanized mice
and were positively selected in pigtail macaques infected with a dual-tropic simian-
human immunodeficiency virus (SHIV) strain (36).
Previously, we demonstrated that an anti-HIV-1 single-chain fragment variant (scFv)
derived from human anti-HIV Env antibody X5, when expressed on the cell surface via
lipid rafts of the plasma membrane through a glycosylphosphatidylinositol (GPI) an-
chor, exhibits extremely potent and broad neutralization activity against diverse HIV-1
strains (37). CD4 T cell lines expressing GPI-anchored scFv X5 (GPI-scFv X5) inhibit a
broad range of R5-, X4-, and dual-tropic strains as well as quasispecies infection. In
addition, GPI-scFv X5 also blocked the transfer of viral particles by dendritic cells to CD4
T cells (W. Wang, C. Ye, and P. Zhou, unpublished data). These results suggest the great
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potential of GPI-scFv X5 as an alternative approach for the engineering of cell resistance
to HIV-1 infection. Hence, we carried out a proof-of-concept study to test the feasibility
of this approach. We interrogated the ability of GPI-scFv X5 to protect human primary
CD4 T cells upon HIV-1 infection and designed a preclinical evaluation of this strategy
in vivo using the hu-PBL NOD/Rag1//IL-2r/ (NRG) mouse model. Lentiviral vec-
tors (lentivectors) encoding GPI-scFv X5 or AB65 (anti-influenza virus hemagglutinin
[HA] control scFv vector) were generated to modify primary CD4 T cells. We show that
transduction of primary CD4 T cells with GPI-scFv X5, but not GPI-scFv AB65, conferred
robust protection of CD4 cells, resulted in a survival advantage, and exerted a negative
effect on HIV-1 replication during infection with R5- or X4-tropic strains both ex vivo
and in vivo. Thus, we developed an easy and feasible approach using GPI-scFv X5 to
protect CD4 T cells from R5- and X4-tropic virus infections ex vivo and in vivo.
RESULTS
Human primary CD4 T cells expressing GPI-scFv AB65 or X5 show comparable
proliferation capacities. To investigate whether GPI-scFv X5 could confer protection
from HIV-1 infection in primary CD4 T cells, we generated lentiviral vector constructs
encoding GPI-scFv X5 or AB65. The latter was derived from an anti-influenza virus HA
antibody and used here as a control. Sequences expressing GPI-scFv along with an HA
tag at the C terminus were linked to a green fluorescent protein (GFP)-encoding
sequence via an internal 2A protein splicing signal. Expression of GPI-scFv and GFP was
under the control of the EF1 promoter (Fig. 1A). Figure 1B shows representative
transduction efficiencies at a multiplicity of infection (MOI) of 5. GPI-scFv X5 or AB65
was highly expressed on CD4 T cells, with 94% and 84.3% GFP-HA-double-positive cells,
respectively. High transduction efficiencies were obtained with cells isolated from
different donors (data not shown). To test whether GPI-scFv X5- or AB65-transduced
cells differed in cell proliferation, 2.5  105 transduced cells were expanded and
maintained in culture medium containing 100 to 300 IU/ml human interleukin-2 (hIL-2).
Figure 1C shows that cells transduced with GPI-scFv X5 had a proliferation rate similar
to that of cells transduced with GPI-scFv AB65, and after a 10-day period of postrans-
duction, the numbers of cells expanded 40-fold. We conclude that GPI-scFv X5- and
AB65-transduced primary CD4 T cells had comparable proliferation capacities.
HIV-1 resistance and survival advantage of GPI-scFv X5-transduced human
primary CD4 T cells ex vivo. To test whether GPI-scFv X5 protects transduced primary
CD4 T cells from HIV-1 infection, untransduced or GPI-scFv X5- or AB65-transduced cells
were infected with HIV R3A (dual tropic), JR-CSF (R5 tropic), or BK132 (X4 tropic) at an
MOI of 0.01 (100 ng p24 per million cells in the presence of 8 ng/ml Polybrene). After
infection, cells were cultured for 9 days. Every 3 days, cells and culture supernatants
were collected, HIV-1 replication was measured by intracellular p24 staining, and the
p24 level in culture supernatants was determined. As expected, untransduced and
GPI-scFv AB65-transduced cells had robust HIV-1 replication after infections by all three
viruses (Fig. 2A and B). In contrast, only 3% of GPI-scFv X5-transduced cells were
infected by R3A, BK132, or JR-CSF (Fig. 2A). On day 9 postinfection, p24 levels in culture
supernatants of GPI-scFv X5-transduced cells were 40- to 70-fold lower for R3A, 6- to
10-fold lower for BK132, and 30- to 50-fold lower for JR-CSF infection than those in
untransduced or GPI-scFv AB65-transduced control cells (Fig. 2B).
To investigate whether GPI-scFv X5-transduced cells resist to cell-to-cell spread,
infected or uninfected primary CD4 T cells were cocultured with untransduced or
GPI-scFv AB65- or X5-transduced cells. Both GFP-positive (GFP) and GFP-negative
GPI-scFv AB65-transduced cells were infected, whereas only GFP-negative GPI-scFv
X5-transduced cells were infected by HIV-1 BK132 (Fig. 2C) as well as JR-CSF and R3A
(data not shown). These data show that GPI-scFv X5-transduced CD4 T cells are resistant
to not only free virus infection but also cell-to-cell spread of HIV-1.
To test whether GPI-scFv X5-transduced cells should be protected and have a
survival advantage, we measured the percentage of scFv-transduced cells in the
coculture system. When GPI-scFv X5-transduced cells were cocultured with infected
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CD4 cells, the percentage of GPI-scFv-positive cells increased over the course of
coculture. However, GPI-scFv X5-transduced cells cocultured with uninfected cells or
GPI-scFv AB65-transduced cells cocultured with infected or uninfected cells had no
selection of scFv-positive cells. As a result, the percentages of GFP GPI-scFv X5-
transduced cells cocultured with infected CD4 cells were significantly higher than those
of GPI-scFv AB65-transduced cells cocultured with infected CD4 cells (P 0.01 or 0.001)
(Fig. 2D). Of note, the strength of selection was relevant to the pathogenesis of virus
strains. GPI-scFv X5-transduced cells were rapidly selected by highly pathogenic strains
R3A and BK132, while selection was relatively slow for lowly pathogenic strain JRCSF.
Taken together, GPI-scFv X5-transduced primary CD4 T cells are resistant to both
cell-free and cell-associated HIV-1 infections.
Equal engraftment efficiencies of GPI-scFv X5- and AB65-transduced human
CD4 T cells among all hu-PBL mice. To explore the therapeutic potential of GPI-scFv
X5-transduced human CD4 T cells, we used a hu-PBL mouse model with an experi-
FIG 1 Human primary CD4 T cells expressing GPI-scFv AB65 or X5 show comparable levels of proliferation. (A) Schematic diagram of the
lentiviral vector expressing GPI-scFv. Sequences encoding GPI-scFv AB65 or X5 with an HA tag at the C terminus are linked to
GFP-encoding sequences via a 2A signal. The GPI signal is derived from the C-terminal 34 amino acids of delay-accelerating factor (DAF).
The expression cassette is driven by the EF1 promoter in the pRRL lentiviral vector. RSV, respiratory syncytial virus; RRE, Rev response
element; cPPT, central polypurine track; WPRE, woodchuck hepatitits virus posttranscription regulatory element. (B) Expression of GPI-scFv
AB65 or X5 in primary CD4 T cells. CD4 T cells were isolated and activated with anti-CD3/anti-CD28 beads in the presence of IL-2 for 24
h. Cells were then transduced with the indicated lentiviral vectors. FACS plots show the expression of GPI-scFv at 5 days postransduction.
Representative data from one of five experiments are shown. GFP is on the x axis, and HA is on the y axis. Mock, untransduced cells; X5,
cells transduced with a lentivirus encoding GPI-scFv X5; AB65, cells transduced with a lentivirus encoding GPI-scFv AB65. (C) Growth curve
of CD4 T cells after transduction. Data are from two independent experiments with 2 donors. Error bars represent the SD of data from
biological duplicates of each experiments.
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FIG 2 HIV resistance and survival advantage of GPI-scFv X5-transduced human primary CD4 T cells ex vivo. (A) Percentage of p24-positive cells over the
course of infection. The intracellular p24 level was monitored 3, 6, and 9 days after HIV-1 infection. Results from three independent experiments with 3
donors are summarized. (B) HIV-1 replication was monitored by a p24 ELISA 3, 6, and 9 days after infection. Data are results from one representative
(Continued on next page)
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mental procedure similar to the one reported previously by Perez et al. (19). In this
procedure, human CD4 T cells transduced with GPI-scFv X5 or AB65 were mixed with
HIV-1-infected or uninfected peripheral blood mononuclear cells (PBMCs). Cell mixtures
along with 1  106 resting PBMCs (to enhance engraftment) were cotransfused into
NRG mice (Fig. 3A). This approach resembles “therapeutic” conditions since modified T
cells were cotransfused with infected cells. In vivo protective activity against HIV-1
infection was tested in three independent experiments by using cells from different
donors. In these experiments, mice were randomly assigned to four treatment groups,
defined as (i) X5/uninfected, comprising mice receiving X5-transduced CD4 cells and
uninfected activated PBMCs; (ii) X5/R5 or X5/X4, composed of mice receiving X5-
transduced CD4 cells or HIV-infected activated PBMCs, respectively; (iii) AB65/unin-
fected, comprising mice receiving AB65-transduced CD4 cells and uninfected activated
PBMCs; and (iv) AB65/R5 or AB65/X4, comprising mice receiving AB65-transduced CD4
cells and R5- or X4-tropic HIV-infected activated PBMCs, respectively. Infection of
activated PBMCs was confirmed prior to injection (Fig. 3B and C). Peripheral blood was
collected on the indicated days after infusion and analyzed by flow cytometry. Results
for mice in the X5/uninfected and AB65/uninfected groups were combined and defined
as the uninfected group. Figure 3B shows that at 1 week posttransfusion, mice in the
X5/R5, AB65/R5, and uninfected groups or mice in the other three groups, the X5/X4,
AB65/X4, and uninfected groups, exhibited comparable engraftment, as measured by
human CD45 cell counts in peripheral blood.
Protection of CD4 T cells in peripheral blood by GPI-scFv X5 during HIV-1
infection in vivo. CD4 cell depletion caused by HIV-1 infection in patients is one of the
major syndromes of AIDS. To test whether GPI-scFv X5-transduced CD4 T cells are
protected in the presence of HIV-1 infection in vivo, after transfusion, the percentages
and numbers of CD4 T cells were monitored weekly. Figure 4A shows the gating of CD4
and CD8 T cells in the human CD3 T cell population of representative hu-PBL mice from
each of the three groups 2 weeks after infection with X4-tropic virus. After cotransfu-
sion with R5-tropic virus-infected cells, the average percentages of CD4 T cells in the
CD3 cell population of mice in the uninfected or AB65/R5 group were about 80% at 1
week postinfection, while in mice in the X5/R5 group, the percentage was about 65%.
The average percentages for mice in the AB65/R5 group decreased to below 5% at 3
weeks postinfection (wpi) and were maintained at about 2% until the end of the
experiment. In contrast, the average percentages of CD4 cells in the CD3 cell popula-
tion of mice in the X5/R5 group were significantly higher than those in mice in the
AB65/R5 group from the second week after infection (P  0.05) but were similar to
those in mice in the uninfected group. The difference in the percentages of CD4 cells
between the X5/R5 and AB65/R5 groups reached a maximum of 23-fold (Fig. 4B, left).
Moreover, on average, the CD4 counts in peripheral blood of mice in the X5/R5 group
were 0.5 to 1 log unit higher than those in mice in the AB65/R5 group from 2 weeks
postinfection, but the differences were not statistically significant, except for those at
6 weeks postinfection (Fig. 4C, left).
Similarly, after cotransfusion with X4-tropic virus-infected cells, average percentages
of CD4 T cells dropped to 5% for mice in the AB65/X4 group, while for mice in the X5/X4
group, average percentages of CD4 T cells were similar to those for mice in the
uninfected group and significantly higher than those for mice in the AB65/X4 group.
The maximum difference in the percentages of CD4 T cells between the AB65/X4 and
X5/X4 groups reached 43-fold (Fig. 4B, right). Surprisingly, on average, the CD4 counts
FIG 2 Legend (Continued)
experiment of three. Error bars represent the SD of data from triplicate p24 ELISAs. (C) Intracellular staining of the p24 Gag protein post-HIV-1 infection.
Mock-transduced or GPI-scFv-transduced cells were cocultured with cells infected with R3A, BK132, or JR-CSF. Cells were permeabilized and stained with
anti-p24 antibody. GFP is on the x axis, and p24 is on the y axis. Representative data show intracellular p24 levels after BK132 infection. (D) Percentage
of GFP/HA cells during coculture of infected or uninfected CD4 T cells with the indicated transduced cells. Dashed lines represent transduced cells
cocultured with uninfected CD4 T cells. Solid lines represent transduced cells cocultured with infected CD4 T cells. Error bars represent data from biological
duplicates from one experiment. P values represent the differences between the AB65 and X5 groups. *, P  0.05; **, P  0.01; ***, P  0.001.
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FIG 3 Equal engraftment efficiencies among all hu-PBL mice. (A) Experimental outline of the generation of GPI-scFv X5- or AB65-
transduced CD4 T cells and R5- or X4-tropic HIV-1-infected PBMCs and cotransfusion of transduced CD4 T cells or infected or uninfected
PBMCs along with resting PBMCs into NRG mice. CD4 cells were isolated, stimulated, and transduced. Activated PBMCs from the same
donor were infected with BK132 or JR-CSF and mixed with GPI-scFv AB65- or X5-transduced CD4 T cells. Mixtures of uninfected activated
PBMCs and transduced CD4 T cells were used as uninfected controls. Additionally, 1  106 resting PBMCs were added to mixed cells, as
previously reported (19). The mixtures of cells were injected into NRG mice intravenously (i.v.). Mice were bled every week to monitor
numbers of CD4 cells and GFP-positive cells. At 6 weeks posttransplantation, mice were necropsied, and spleen and bone marrow were
collected for analysis. 8M, 8 million. (B and C) Infection of activated PBMCs prior to infusion. PBMCs were stimulated with anti-CD3/anti-
(Continued on next page)
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for mice in the X5/X4 group were 1 to 3 log units higher than those for mice in the
AB65/X4 group from 2 weeks postinfection, and the differences were statistically
significant (P  0.05) (Fig. 4C, right). This is likely due to the highly pathogenic activity
of the X4-tropic BK132 strain. Thus, we demonstrate that CD4 T cells in hu-PBL mice
FIG 3 Legend (Continued)
CD28 beads. Cells were infected with JR-CSF (B) or BK132 (C) at an MOI of 0.01 or with 100 ng p24 per million cells. Infection was
determined by intracellular staining of HIV-1 Gag p24. (D) Engraftment efficiency of human cells at 1 week posttransplantation. Human
CD45 cell counts were measured (uninfected/R5, n  5; X5/R5, n  9; AB65/R5, n  6; uninfected/X4, n  4; X5/X4, n  10; AB65/X4,
n  10). (Left) Engraftment of infused cells in mice infected with JR-CSF. (Right) Engraftment of infused cells in mice infected with BK132.
Mean values are shown for each group. ns, not significant.
FIG 4 Protection of CD4 T cells in peripheral blood in vivo. (A) Gating of CD4 and CD8 T cells in the human CD3 T cell population of representative hu-PBL mice
from each of the three groups 2 weeks after X4-tropic virus infection. (B) Percentage of human CD4 cells in human CD3 cells in blood during infection.
Percentages of CD4 cells were determined by flow cytometry. (C) CD4 cell counts during HIV-1 infection. Left panels show results from JR-CSF infection; right
panels show results from BK132 infection. *, P  0.05; **, P  0.01; ***, P  0.001. P values represent the differences between the AB65/R5 and X5/R5 groups
and between the AB65/X4 and X5/X4 groups.
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transfused with GPI-scFv X5-transduced cells are protected during infection by both X4-
and R5-tropic viruses.
GPI-scFv X5-transduced CD4 T cells are selected in peripheral blood during
HIV-1 infection. To investigate whether the protection of CD4 cells is due to the
selection of GPI-scFv X5-transduced CD4 T cells in vivo, the percentage of GFP cells in
CD4 cell populations was determined by flow cytometry. Figure 5A shows the gating of
CD4/GFP cells in human CD4 T cell populations of representative hu-PBL mice from
each of the three groups 4 weeks after X4-tropic virus infection. After cotransfusion
with both R5- and X4-tropic virus-infected cells, average percentages of CD4/GFP
cells in mice in the X5/X4 and X5/R5 groups dropped slightly at 2 weeks postinfection
and then gradually increased and remained at 70 to 90% afterwards (Fig. 5B). In
contrast, average percentages of CD4/GFP cells in mice in the uninfected and
AB65/R5 groups gradually decreased from 80% to about 50%. The differences in the
average percentages of CD4/GFP cells between mice in the X5/R5 and AB65/R5
groups as well as between mice in the X5/R5 and uninfected groups were significant
(P  0.01) (Fig. 5B, left). More significantly, average percentages of CD4/GFP cells in
mice in the uninfected and AB65/X4 groups dropped from 80% to about 20%. The
differences in the average percentages of CD4/GFP cells between mice in the X5/X4
and AB65/X4 groups as well as between mice in the X5/X4 and uninfected groups were
very significant (from P values of 0.01 to P values of 0.001) (Fig. 5B, right). Thus,
these results strongly suggest that a selective advantage for GPI-scFv X5-transduced
CD4 T cells occurs during both R5- and X4-tropic HIV-1 infections.
GPI-scFv X5-transduced CD4 T cells reduce HIV-1 replication in hu-PBL mice.
We analyzed replication kinetics in individual mice cotransfused with different cells.
FIG 5 Selection of GPI-scFv X5-transduced cells in peripheral blood in vivo. (A) Gating of CD4/GFP cells in human CD4 T cell populations
of representative hu-PBL mice from each of the three groups 4 weeks after X4-tropic virus infection. (B) Percentage of CD4/GFP cells
in human CD4 T cells in mouse blood during infection. Percentages of GFP cells were determined by flow cytometry. Left panels show
results from JR-CSF infection; right panels show results from BK132 infection. *, P  0.05; **, P  0.01; ***, P  0.001. P values represent
the differences between the AB65/R5 and X5/R5 groups and between the AB65/X4 and X5/X4 groups.
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One week after cotransfusion with R5-tropic virus-infected cells, the average plasma
HIV-1 RNA load was 3,509 copies/ml in X5/R5 mice, while it was 53,771 copies/ml in
mice in the AB65/R5 group (P  0.01). At later time points, plasma viremia increased
significantly in both groups. However, the average plasma viral loads for the X5/R5
group were significantly lower than those for the AB65/R5 group (P  0.05 or P  0.01)
(Fig. 6A, left). One week after cotransfusion with X4-tropic virus-infected cells, the
average plasma viral RNA load was 642 copies/ml in mice in the X5/X4 group, while it
was 627,274 copies/ml in mice in the AB65/X4 group (P  0.0001). HIV-1 plasma loads
increased significantly in both groups of mice from 2 to 6 wpi. The total plasma viral
loads in mice in the X5/X4 group were actually higher than those in mice in the
AB65/X4 group (Fig. 6A, right).
Because X4-tropic HIV-1 infection led to a dramatic depletion of CD4 T cells, the
average CD4 T cell counts in mice in the X5/X4 group were significantly higher than
those in mice in the AB65/X4 group (Fig. 4C), suggesting that the more profound CD4
depletion in mice in the AB65/X4 group than in mice in the X5/X4 group may be
responsible for the lower viral loads seen in mice in the AB65/X4 group at 1 week
posttransfusion. We therefore also calculated the number of HIV-1 RNA copies per CD4
cell. We show that 1 week after cotransfusion with R5-tropic virus-infected cells, the
average number of viral RNA copies per CD4 cell in mice in the X5/R5 group was 49
times lower than that in mice in the AB65/R5 group (P  0.001). During the 6 weeks
posttransfusion, the numbers of HIV-1 RNA copies/CD4 cell in mice in the X5/R5 group
were significantly lower than those in mice in the AB65/R5 group (P  0.01 or P 
0.001) (Fig. 6B, left). Similarly, 1 week after cotransfusion with X4-tropic virus-infected
cells, the average number of viral RNA copies per CD4 cell in mice in the X5/X4 group
was 4,783 times lower than that in mice in the AB65/X4 group (P 0.0001). Afterwards,
the numbers increased in both groups of mice. However, the numbers in mice in the
FIG 6 GPI-scFv X5-transduced CD4 T cells reduce blood viral loads in hu-PBL mice. (A) Temporal viral load curve. (B) Temporal
normalized numbers of viral RNA copies per CD4 cell in plasma. (Left) Data from JR-CSF infection. (Right) Data from BK132
infection. (Top) Viral loads throughout the experiment. Data represent average viral loads in infected mice. (Bottom) Numbers
of viral RNA copies per CD4 cell throughout the experiment. Data represent average numbers of viral RNA copies per CD4 cell.
*, P  0.05; **, P  0.01; ***, P  0.001.
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X5/X4 group were still significantly lower than those in mice in the AB65/X4 group
(P  0.05 to P  0.0001) (Fig. 6B, right). Taken together, we conclude that GPI-scFv
X5-transduced CD4 T cells indeed exert a negative effect on viral loads in hu-PBL mice.
GPI-scFv X5-transduced CD4 T cells are selected in lymphoid tissues during
HIV-1 infection. At 6 weeks posttransfusion, mice were necropsied, and splenocytes
and bone marrow cells were isolated. The numbers of GPI-scFv X5- or AB65-transduced
CD4 T cells as well as HIV-1 replication in lymphoid tissues were measured. Figure 7A
shows that consistent with the results observed for peripheral blood, mice in the X5/R5
group, while similar to mice in the uninfected group, had significantly higher average
percentages of CD4 T cells in spleen (29.12%) than did mice in the AB65/R5 group
(6.27%) (P  0.0329). Mice in the X5/R5 group, while similar to mice in the uninfected
group, also had a significantly higher average percentage of CD4 T cells in bone
marrow (33.58%) than did mice in the AB65/R5 group (8.91%) (P  0.0283).
Similarly, after cotransfusion with X4-tropic virus-infected cells, mice in the X5/X4
group, while similar to mice in the uninfected group, had a significantly higher average
percentage of CD4 T cells in spleen (31.58%) than did mice in the AB65/X4 group
(0.43%) (P  0.0027). Mice in the X5/X4 group, while similar to mice in the uninfected
group, also had a significantly higher average percentage of CD4 T cells in bone
marrow (29.41%) than did mice in the AB65/X4 group (4.49%) (P  0.0032) (Fig. 7B).
Thus, the survival advantage for CD4 T cells was also observed in spleens and bone
marrow of mice transfused with GPI-scFv X5-transduced CD4 T cells compared with
mice transfused with GPI-scFv AB65-transduced CD4 T cells.
Figure 7C shows that, consistent with the results observed for peripheral blood,
mice in the X5/R5 group had a significantly higher average percentage of HA/GFP
cells in spleen (25.02%) than did mice in the AB65/R5 and uninfected groups (6.24%
and 7.57%, respectively) (P 0.001 and P 0.01, respectively). Mice in the X5/R5 group
also had a significantly higher average percentage of HA/GFP cells in bone marrow
(17.75%) than did mice in the AB65/R5 and uninfected groups (8.61% and 6.14%,
respectively) (P  0.05 and P  0.01, respectively).
Similarly, after cotransfusion with X4-tropic virus-infected cells, mice in the X5/X4
group had a significantly higher average percentage of HA/GFP cells in spleen
(85.38%) than did mice in the AB65/X4 and uninfected groups (36.71% and 15.58%,
respectively) (P 0.0012 and P 0.001, respectively). Mice in the X5/X4 group also had
a significantly higher average percentage of HA/GFP cells in bone marrow (83.94%)
than did mice in the AB65/X4 and uninfected groups (42.97% and 12.28%, respectively)
(P  0.0034 and P  0.001, respectively) (Fig. 7D). Thus, these results further demon-
strate that GPI-scFv X5 was stably expressed in vivo and that GPI-scFv X5-transduced
CD4 T cells were selected in lymphoid tissues during HIV-1 infection.
GPI-scFv X5-transduced CD4 T cells reduce HIV-1 replication in lymphoid
tissues in hu-PBL mice. To test the effect of GPI-scFv-transduced CD4 T cells on HIV-1
replication in lymphoid tissues, we measured HIV-1 DNA or RNA copy numbers in
splenocytes and bone marrow cells and calculated the number of DNA or RNA copies
per CD3/CD8 cell to include both CD4 T cells and HIV-infected CD4 T cells with
downregulated CD4 expression (38). Figure 8A shows that mice in the X5/R5 group had
significantly lower HIV-1 DNA copy numbers per human CD4 T cell in spleens than did
mice in the AB65/R5 group (P  0.0496). Mice in the X5/R5 group also had lower
average DNA copy numbers per human CD4 T cell in bone marrow than did mice in the
AB65/R5 group (but no statistically significant difference [P  0.1135]). Similarly, after
cotransfusion with X4-tropic virus-infected cells, mice in the X5/X4 group had 11 times
fewer HIV-1 DNA copies per human CD4 T cell in spleens than did mice in the AB65/X4
group (P  0.0076). Mice in the X5/X4 group also had 12 times fewer average HIV-1
DNA copies per CD4 T cell in the bone marrow than did mice in the AB65/X4 group
(P  0.0032) (Fig. 8B).
We also measured the HIV-1 RNA levels in lymphoid tissues. Figure 8C shows that
mice in the X5/R5 group had significantly lower average HIV-1 RNA copy numbers
than did mice in the AB65/R5 group in spleens (P  0.0496) or in bone marrow
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(P  0.0879). Similarly, after cotransfusion with X4-tropic virus-infected cells, mice
in the X5/X4 group had 10 times fewer average HIV-1 RNA copies per CD4 T cell
than did mice in the AB65/X4 group in spleens (P  0.0004) or 7 times fewer copies
in the bone marrow (P  0.0133) (Fig. 8D). Taken together, we conclude that
FIG 7 Selection of GPI-scFv X5-transduced human CD4 T cells in lymphoid tissues during HIV-1 infection in vivo.
Shown are percentages of CD4 cells in CD3 T cells (A and B) and scFv-positive cells in CD4 T cells (C and D) from
mouse spleen or bone marrow. (A and C) Data from mice infected with JR-CSF. (B and D) Data from mice infected
with BK132. Spleen and bone marrow cells were collected on the day of euthanasia. Cells were stained as described
in Materials and Methods. Mice with very low numbers of CD4 T cells were excluded when the counts determined
by flow cytometry were below 10. Mean values for each group are shown.
Ye et al. Journal of Virology
February 2017 Volume 91 Issue 3 e01389-16 jvi.asm.org 12
GPI-scFv X5-transduced CD4 T cells exert a negative effect on viral replication in
lymphoid tissues in hu-PBL mice.
DISCUSSION
In the present study, we employed GPI-scFv X5, which is derived from human
anti-HIV-1 monoclonal antibody (MAb) X5, to confer resistance of primary CD4 T cells
FIG 8 Negative effect of GPI-scFv X5-transduced CD4 T cells on viral replication in lymphoid tissues. Shown are
normalized HIV-1 DNA (A and B) and RNA (C and D) copy numbers in spleen and bone marrow. HIV-1 DNA or RNA
copy numbers were divided by CD3 CD8 cell counts. (A and C) Data from mice infected with JR-CSF. (B and D)
Data from mice infected with BK132. Spleen and bone marrow cells were collected on the day of euthanasia. Due
to very low cell recovery, the result for one mouse in the X5/X4 group was excluded. Mean values for each group
are shown.
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to HIV-1 infection. We show that GPI-scFv X5-transduced CD4 T cells were resistant to
R5-, X4-, and dual-tropic virus infections and displayed a survival advantage in the
presence of HIV-1 strains ex vivo. In a preclinical study using a semitherapeutic strategy
in hu-PBL mice, we show that after cotransfusion with R5-tropic virus-infected cells,
averages of 2- to 15-fold reductions in viral loads as well as 5- to 400-fold reductions
in the number of viral RNA copies per CD4 cell were observed for mice in the X5/R5
group compared to those for mice in the AB65/R5 group, and after cotransfusion with
X4-tropic virus-infected cells, averages of 13- to 4,000-fold reductions in the number of
viral RNA copies per CD4 cell were observed for mice in the X5/X4 group compared to
those for mice in the AB65/X4 group throughout the experiments (Fig. 6). Moreover, we
show that there was significant protection of CD4 T cells in peripheral blood, spleen,
and bone marrow in mice in the X5/R5 and X5/X4 groups compared to mice in the
AB65/R5 and AB65/X4 groups (Fig. 4B and C and 7A). In the presence of R5- or X4-tropic
virus, GPI-scFv X5-transduced cells were enriched 1.8- or 4.4-fold in peripheral blood,
3.3- or 5.5-fold in spleens, and 2.9- or 6.8-fold in bone marrow, respectively (Fig. 5B and
7B), implying a selective advantage for GPI-scFv X5-transduced cells in vivo. Thus, these
results strongly suggest that GPI-scFv X5 protects CD4 T cells from depletion not only
by R5-tropic virus but also by X4-tropic virus infection and has a great potential to be
a therapeutic candidate for HIV-1 gene therapy.
Extensive studies have been carried out to evaluate the feasibility of entry inhibition.
The most promising study utilized a disruption of the CCR5 gene by ZFN. A recent
clinical trial using autologous CD4 cells modified by ZFN/CCR5 demonstrated a de-
crease in the viral load by an average of 1.2 log units from peak viremia during
treatment disruption for 4 out of 6 patients (24). However, the possible appearance of
X4-tropic virus in the late stages of the disease requires approaches to engineer HIV-1
target cell resistance to X4- or R5X4-tropic virus. Wilen et al. reported partial protection
of CXCR4-edited CD4 cells in humanized mice (28). Env sequencing and tropism testing
showed that a shift to CCR5 usage by the virus accounted for the depletion of
CXCR4-disrupted cells at later time points. It seems that the ablation of both CCR5 and
CXCR4 confers full protection against HIV-1 infection for all three tropisms (31, 39).
Although gene editing provides a permanent and lifelong inherited phenotype for
progeny cells of modified cells, potential off-target effects should be carefully investi-
gated when this strategy is applied to clinical use, especially in light of the high level
of homology between the CCR5 and CCR2 genes (40, 41). Additionally, the relatively
lower efficiency of genome editing by ZFN or other nucleases limits the amount of
biallelic disrupted cells for a given number of cells for infusion. Another drawback with
the CCR5 gene knockout strategy is the potential for disease exacerbation. For example,
it has been shown that trafficking of CCR5 gene knockout leukocytes to the central
nervous system (CNS) after West Nile virus infection is reduced, leading to more severe
disease (42, 43). Thus, in the present study, we delivered GPI-scFv X5 at an 80% average
transduction efficiency to human primary T cells using a lentiviral vector. Since the
safety of gene transfer by lentiviral vectors (44) has been demonstrated in several
clinical trials, our approach is able to achieve a large amount of infection-resistant cells
by a single low dose (MOI of 5) for transduction.
X5 is a human monoclonal Fab neutralizing antibody selected by the gp120-CD4-
CCR5 fusion complex from an antibody phage display library and significantly neutral-
izes primary HIV-1 isolates (45). It recognizes a CD4-inducible epitope located in the
coreceptor-binding site (amino acid residues 417 to 432) of gp120 (46, 47). It was
reported previously that the scFv form of X5 is more effective than the Fab fragment
or the whole antibody in neutralization (48). It is likely that after gp120-CD4 binding,
the available space is not sufficient to accommodate large molecules. Despite the broad
range of neutralization activities of X5, we and others showed that free scFv X5 had a
relatively lower level of inhibition of virus entry (37, 49). X5 function is great enhanced
by the addition of soluble CD4. In this way, GPI-anchored scFv X5 may efficiently
capture the epitope exposed after virus attachment to target cells and block virus
fusion at an early stage, since CD4 resides in the lipid raft membrane. Although the
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inhibitory activity of GPI-scFv X5 expressed on human CD4 T cell lines was demon-
strated previously by our group, the in vivo function of GPI-scFv X5-transduced primary
CD4 T cells addressed in the present study extends these findings to a more clinically
relevant system.
A limitation of the present study is that the prolonged therapeutic impact of
GPI-scFv X5 has not been addressed. In this proof-of-concept study, we have shown
vigorous protection by GPI-scFv X5 in a humanized mouse model of acute HIV infection.
We have also shown the persistent expression of GPI-anchored scFv (X5 and control
AB65) within lymphoid tissues at the end of in vivo experiments (Fig. 7B). However,
since the human T cells transplanted into mice resulted in xenogeneic graft-versus-host
activity, we were not able to investigate longer effects of modified cells on HIV infection
and immune cell repopulation. Moreover, the effect of GPI-scFv X5 on chronic infection
and the influence of ex vivo manipulation on cell proliferation, immune function,
persistence, and homing should be studied further. Previous clinical studies described
the maintenance of cells modified by gene transfer for up to a decade (50–52), and
these cells were detected in rectal mucosa, implying persistence and trafficking to
various organs of modified cells. Interestingly, a similar approach using membrane-
anchored C-peptide entry inhibitor (mC46)-expressing hematopoietic stem cell trans-
plantation in pigtail macaques showed that modified SHIV-specific CD4 T cells were
maintained in mC46-treated animals (36). A more robust T lymphocyte response,
including gamma interferon (IFN-) production and an enhanced production of anti-
bodies against SHIV, was also observed in animals transfused with mC46-treated cells.
Whether these enhanced immunological responses are mC46 specific or beneficial for
protected SHIV-1-resistant CD4 cells (or other myeloid cells) should be investigated
further. Thus, the next step is to test GPI-scFv X5-transduced autologous CD4 T cells in
an SHIV-challenged macaque model.
Because GPI-scFvs contain human VH and VL gene segments and an artificial linker,
expression of the scFvs on the cell surface may lead to immune-mediated rejection of
cells expressing GPI-scFvs when used in human patients in a clinical setting. However,
such immune-mediated rejection did not occur in the studies of mC46 (a membrane-
bound version of C46) described above (36, 53). In both an immunocompetent ma-
caque model as well as a phase I human trial, mC46-modified macaque hematopoietic
stem cells or mC46-modified autologous human CD4 T cells expanded in the host,
without significant host immune responses to mC46. Nonetheless, it is possible that
GPI-scFvs may be immunogenic, and it will be important to test their immunogenicity
in immunocompetent hosts in vivo. Finally, a single use of GPI-scFv X5 may lead to
escape mutants in long-term infections in clinical settings. Therefore, a mixture of
GPI-anchored antibody derivatives, such as GPI-scFv X5 and trimeric GPI-HCDR3 PG16
(54), that target different epitopes in HIV-1 Env could be preferable.
MATERIALS AND METHODS
Ethics statement. All experiments using human blood and all animal experiments were conducted
according to guidelines for the housing and care of laboratory animals (60) and in accordance with
protocols approved by the Institutional Animal Care and Use Committee (IACUC) (approval 14-100.0) at
the University of North Carolina at Chapel Hill. Human blood was purchased from the Gulf Coast Regional
Blood Center, Houston, TX.
Lentiviral vector production and titration. Lentiviral vectors were generated by using transient
transfection of HEK293T cells (American Type Culture Collection [ATCC]) with calcium phosphate and the
lentivectors pRRL, encoding GPI-anchored scFvs; delta 8.9, encoding Gag/Pol/Rev; and pLP/VSVG; en-
coding the vesicular stomatitis virus G (VSVG) envelope, as described previously (22). Cell culture
supernatants were collected at 48 h posttransfection and concentrated via ultracentrifugation at 25,000
rpm for 2 h at 4°C. Concentrated lentivectors were resuspended in serum-free RPMI 1640 and titrated by
the transduction of HEK293T cells. Titers of concentrated lentivectors were calculated by quantification
of the number of GFP-positive cells 2 days after transduction.
Human primary CD4 T cell culture and transduction. Methods for the isolation of human PBMCs
were described previously (55), and PBMCs were cryopreserved until use. CD4 T cells were negatively
isolated from PBMCs by using an untouched Dynabeads human CD4 T cell kit (catalog number 11352D;
Invitrogen) according to the manufacturer’s instructions. Isolated CD4 T cells were stimulated with
anti-CD3/anti-CD28-coated magnetic beads (catalog number 11131D; Gibco) at a bead-to-cell ratio of 1:1
and maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) plus 100 to
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300 IU/ml human recombinant IL-2 (NIH AIDS Reagent Program) (here referred to as complete RPMI
medium). Twenty-four hours after stimulation, concentrated lentiviral vectors were added to cells at an
MOI of 5. Beads were removed at day 5 after stimulation. Transduction efficiency was determined as the
percentage of GFP-positive cells determined by using fluorescence-activated cell sorter (FACS) analysis.
Transduced T cells were expanded and maintained in complete RPMI.
Flow cytometry. All staining procedures except intracellular staining were performed on ice in FACS
buffer (phosphate-buffered saline [PBS] containing 2% FBS and 2 mM EDTA). Intracellular staining was
performed by using a BD Cytofix/Cytoperm kit (catalog number 554714) according to the manufacturer’s
instructions. The HA tag was detected by staining of cells with rabbit anti-HA antibody (catalog number
H6908; Sigma) followed by a secondary Alexa Fluor 647-conjugated anti-rabbit IgG antibody (clone
poly4064; BioLegend). Phycoerythrin (PE)-conjugated anti-p24 antibody (clone KC57; Beckman Coulter)
was used to detect intracellular HIV-1 Gag proteins. Other antibodies used in ex vivo experiments were
(i) PE-CD4 (clone OKT4; BioLegend) and 7-aminoactinomycin D (catalog number A1310; Life Technolo-
gies) for cell counting and (ii) Live/Dead yellow dye (catalog number L34959; Life Technologies) and
peridinin chlorophyll protein (PerCP)/Cy5.5-CD4 (clone OKT4; BioLegend) for infection staining. Other
antibodies used for in vivo experiments were (i) PE-human CD45 (clone HI30; BioLegend), PE/Cy7-CD3
(clone OKT3; BioLegend), and 7-aminoactinomycin D for cell counting and (ii) Live/Dead yellow dye,
Pacific Orange-mouse CD45 (reference number MCD4530; Life Technologies), allophycocyanin (APC)/
Cy7-human CD45 (clone HI30; BioLegend), Pacific Blue-CD3 (clone UCHT1; BioLegend), PerCP/Cy5.5-CD4
(clone OKT4; BioLegend), and PE/Cy7-CD8 (clone HIT8a; BioLegend) for surface marker staining. Cell
counting and analysis were performed by using a Guava easyCyte flow cytometer (Millipore). Other
staining samples were run on a BD LSR Fortessa or Canto II instrument. Results were analyzed by using
FlowJo 10.0.7 (TreeStar).
Ex vivo HIV-1 challenge. X4-tropic strain BK132, R5-tropic strain JRCSF, and R5X4-dual-tropic strain
R3A were used for ex vivo challenges. R3A and JR-CSF were generated by transfection of HEK293T cells.
BK132 was obtained from the NIH AIDS Reagent Program and propagated in activated CD4 T cells. Virus
stocks were titrated on MagiX4R5 cells and analyzed by a p24 enzyme-linked immunosorbent assay
(ELISA). Human primary CD4 T cells were stimulated and transduced as described above. A total of 1 
106 stimulated cells were infected with R3A, JR-CSF, or BK132 at an MOI of 0.01 or with 100 ng p24 per
million cells in the presence of 8 ng/ml Polybrene via spinning at 1,500  g for 2 h at 37°C. Cells were
then washed with RPMI 1640 twice and resuspended in 1.5 ml complete RPMI medium on a 12-well plate.
At days 3, 6, and 9 postinfection, supernatants were collected and stored at 20°C for further p24
detection via an ELISA. Cells were counted after Live/Dead staining and CD4 surface staining. HIV-1
infection was determined by flow cytometry. Cells were stained for the surface HA tag and CD4 marker,
followed by intracellular staining of the p24 Gag protein. For the coculture system, 5  105 primary CD4
cells were infected with R3A, JR-CSF, or BK132 at a dose of 100 ng p24 per million cells. Cells were then
washed with medium and added to uninfected untransduced or GPI-scFv X5- or AB65-transduced cells,
respectively. HIV-1 infection was determined by intracellular p24 staining as described above.
In vivo testing of GPI-scFv X5-transduced human CD4 T cells using a hu-PBL mouse model. A
total of three in vivo experiments were carried out. In each experiment, cells from one healthy human
donor were used to generate GPI-scFv X5- or AB65-transduced primary CD4 T cells, HIV-1-infected and
uninfected PBMCs, and resting PBMCs. NRG mice (Jackson Laboratory) were irradiated as previously
described (56). In each experiment, mice at 4 to 6 weeks of age were randomly assigned to 4 groups
(n  2 to 3 for each uninfected group and n  6 to 10 for each infected group) to control for sex and
age effects. CD4 T cells were stimulated, transduced, and expanded as described above. Resting PBMCs
were stimulated with CD3/CD28 beads. Beads were removed 3 days after stimulation. Cells were allowed
to recover for 2 days and then infected with JR-CSF or BK132 at an MOI of 0.01. On the day of transfusion,
8  106 GPI-scFv X5- or AB65-transduced CD4 T cells with 1  106 uninfected or infected PBMCs in 200
l PBS were injected into each mouse via tail vein. Additionally, 1  106 autologous resting PBMCs were
also injected into each mouse to promote engraftment, using methods similar to those reported
previously by Perez et al. (19).
Engraftment efficiency was assessed at day 7 posttransfusion by counting human CD45 cells in
mouse blood using a flow cytometer. Blood was bled through the tail vein, and plasma was isolated by
centrifugation at 5,000 rpm for 5 min and stored at80°C for further viral RNA extraction. For cell pellets,
red blood cells were lysed by using Ammonium-Chloride-Potassium (ACK) lysis buffer (catalog number
A1049201; Gibco) at room temperature for 5 min. Cells were then resuspended in FACS buffer and
stained for surface markers, including mCD45, hCD45, CD3, CD4, CD8, and the HA tag, followed by flow
cytometry analysis. Cells were counted by using a Guava easyCyte flow cytometer (Millipore) after
staining of live/dead cells and human CD45 and CD3.
At 6 weeks posttransfusion, splenocytes and bone marrow cells were isolated following euthanasia.
Single-cell suspensions were obtained by passing cells through a 70-m filter. Surface markers, including
mCD45, hCD45, CD3, CD4, CD8, and the HA tag, were analyzed by flow cytometry after staining. Genomic
DNA and total RNA were isolated from splenocytes and bone marrow cells by using a DNeasy blood and
tissue kit (Qiagen) and an RNeasy Mini Plus kit (Qiagen), respectively.
Measurement of viral loads in plasma samples. The viral load was determined as previously
described (57, 58). Briefly, viral RNA from each mouse and standard plasma (catalog number 3443; NIH
AIDS Reagent Program) were extracted (QIAamp viral RNA minikit; Qiagen) from plasma of infected
humanized mice and analyzed by reverse transcription-quantitative PCR (RT-qPCR) (TaqMan One-Step
RT-qPCR master mix; ABI). The primers and probe used for RT-qPCR were forward primer 5=-CAATGGC
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AGCAATTTCACCA-3=, reverse primer 5=-ATGCCAAATTCCTGCTTGA-3=, and probe FAM (6-carboxyfluores
cein)-CCCACCAACAGGCRGCCTTAACYG-QSY7 (TAMRA [6-carboxymethyltetrarhodamine]).
Measurement of HIV-1 DNA or RNA levels. Total spleen or bone marrow cells corresponding to
1  105 human CD45 cells were lysed. Genomic DNA was extracted according to the manufacturer’s
instructions (DNeasy blood and tissue kit; Qiagen). A total of 1 106 ACH2 cells were serially diluted and
mixed with human PBMCs from a healthy donor to obtain a total of 1  106 cells. Genomic DNAs from
ACH2 cell-PBMC mixtures were used as standard samples. Cell-associated RNA and RNA standards were
extracted by using an RNeasy Mini Plus kit (Qiagen) and reverse transcribed into first-strand cDNA
(Superscript III reverse transcriptase; Invitrogen). HIV-1 DNA copies and cDNA copies were detected by
quantitative PCR (TaqMan Universal master mix; Applied Biosystems) using the primers and probe
described above, and copy numbers were calculated according to standard curves.
Statistical analysis. Statistical analysis was performed by using GraphPad Prim software version 5.0.
Averages and standard deviation (SD) were calculated. Unpaired two-tailed t tests with Welch’s correc-
tion or Mann-Whitney U tests were used to compare data between two groups. All results were
considered significant when the P value was 0.05.
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